There is no published human clinical trial of injected GHK-Cu at any dose. The injection protocols circulating online — typically 1–2 mg per day in 30-day cycles — come from peptide retailers and forums, not from published research. The evidence that does exist in people is for topical copper peptide, studied over 8 to 12 weeks of twice-daily use. And as of 2026, the FDA treats the two routes very differently: non-injectable GHK-Cu sits on the agency’s Category 1 compounding list, while the injectable nomination has been withdrawn entirely.
That is an uncomfortable answer if you came here for a dosing chart. It is also the honest one, and it is the reason this page reads differently from the other results you will find. Below is what is actually published, where the popular numbers come from, what the current regulatory position is, and how dosing is decided at our Beverly Hills peptide practice — which is by clinical evaluation, not by a chart.
What GHK-Cu is and how it works
GHK is a naturally occurring tripeptide — glycyl-L-histidyl-L-lysine — that your body already makes. It sits within the alpha-2(I) chain of type I collagen and is released by proteolysis when tissue is injured. Plasma levels decline with age, from roughly 200 ng/mL around age 20 to about 80 ng/mL by age 60.
GHK binds copper(II) with high affinity, and the resulting complex — GHK-Cu — stimulates synthesis of collagen, certain glycosaminoglycans and the proteoglycan decorin, while modulating matrix metalloproteinases and their inhibitors. In plain terms: it appears to act as a repair signal, telling skin and connective tissue to rebuild rather than simply to inflame. It also shows antioxidant activity, inactivating lipid-peroxidation byproducts such as 4-hydroxynonenal and malondialdehyde.
You will also see the claim that GHK modulates roughly a third of the human genome. That figure — 31.2% of human genes changed by 50% or more, 59% of them upward — is reported by Pickart and Margolina in International Journal of Molecular Sciences, 2018. It is worth knowing two things about that source before you lean on it: it is a review rather than a primary dataset, and both authors are affiliated with a commercial GHK-Cu skincare company founded by the compound’s discoverer. The science is interesting. The provenance deserves stating.
Topical GHK-Cu: what the human studies actually used
Topical is where the human evidence lives, and even here it is thinner than the marketing implies. The studies that every article cites trace back to the same handful of references:
| Study | Participants | Duration | Publication type |
|---|---|---|---|
| Leyden et al., facial cream, 2002 | 71 women with photoaging | 12 weeks | Conference abstract, not peer-reviewed |
| Leyden et al., eye cream, 2002 | 41 women, periorbital | 12 weeks | Conference abstract, not peer-reviewed |
| Abdulghani et al., 1998 | Pilot, thigh skin | 12 weeks | Journal article, self-described pilot |
| Badenhorst et al., 2016 | Randomized, double-blind | 8 weeks | The only true RCT in the set |
Reported effects were increases in skin density and thickness, reduced laxity, and reduced fine lines. Badenhorst and colleagues reported a 31.6% reduction in wrinkle volume against a comparator peptide complex, and 55.8% against a control serum.
Here is the part nobody mentions: none of those human studies states a GHK-Cu concentration. The widely quoted “2–4% topical” figure is not traceable to any of them. The only concentrations in the underlying literature are laboratory values in cultured fibroblasts, in the nanomolar range. If a product tells you its percentage, that is the manufacturer’s formulation decision, not a dose validated in a trial.
Practical points that are well founded: copper(II) catalyses the oxidation of ascorbic acid, and low pH destabilises the peptide-copper complex. Layering a copper peptide with a low-pH vitamin C serum or an AHA in the same application degrades both. Use them at different times of day.
Injectable GHK-Cu: why we will not publish a protocol
Search “GHK-Cu injection dosage” and you will find confident charts: 1–2 mg daily subcutaneously, 30 days on, a break, repeat. Some sites specify injection sites and reconstitution volumes to the decimal.
None of it comes from a published human study, because there isn’t one. That is not our opinion — it is confirmed from three independent directions. The most comprehensive pro-GHK review in existence, written by the compound’s own discoverer, describes no human injection study and no human injected dose; its only systemic-administration passage covers mice, rats and pigs, and cites a patent rather than a trial. The FDA’s own position statement says there are limited data in humans. And no completed interventional trial of injectable GHK-Cu appears in the registries.
For scale, the closest thing to a human injectable figure anywhere in the literature is an allometric extrapolation from a rat study, in which the same review speculates a human “might” respond to roughly 35 micrograms. That is 30 to 60 times lower than the milligram protocols sold online. We cite that contrast not as a recommendation but to show how wide the gap is between what is published and what is circulating.
A clinic that hands you a number it cannot source is not being generous. It is transferring risk to you.
The 2026 regulatory picture, stated by route
This is where most pages on this topic are simply out of date, and where the detail matters. The FDA treats injectable and non-injectable GHK-Cu as two different questions, and the position changed twice in 2026.
| Date | What changed |
|---|---|
| Sept 2023 | GHK-Cu except for injectable routes placed in Category 1 of the FDA’s 503A bulk drug substances list. GHK-Cu for injectable routes placed in Category 2, citing significant safety risks. |
| Apr 2026 | GHK-Cu removed from Category 1 because the nominations were withdrawn by the nominators. |
| May 2026 | A nominator clarified it had withdrawn only the injectable nomination. Non-injectable GHK-Cu was added back to Category 1. |
| Current | Category 1 contains GHK-Cu except for injectable routes. The injectable nomination has been withdrawn, so it is no longer under active consideration. The FDA has said it intends to consult its Pharmacy Compounding Advisory Committee on GHK-Cu before the end of February 2027. |
Two things follow, and both are commonly got wrong.
First, writing “GHK-Cu is Category 1” or “GHK-Cu is Category 2” without naming the route is inaccurate in either direction. Second — and this is the one that trips people up — the withdrawal of the injectable nomination did not make injectable GHK-Cu more available. It moved from “nominated but flagged as a significant safety risk” to “not nominated at all,” which removes even the theoretical route to enforcement discretion. Any coverage framing the 2026 change as a loosening has it backwards.
The FDA’s stated reason for the original Category 2 placement is worth quoting exactly, because it is not what most people assume: compounded injectable drugs containing GHK-Cu “may pose risk for immunogenicity due to the potential for aggregation and peptide-related impurities,” and “there are limited data in humans to inform safety-related considerations.” The concern on record is immunogenicity and impurities, not copper toxicity.
Also worth correcting: GHK-Cu has never been FDA-approved as a drug. A copper-peptide gel did receive a 510(k) device clearance as a wound dressing in the 1990s. Device clearance is not drug approval, and the two are routinely conflated in marketing copy.
Topical sits in a different regime altogether. Cosmetics do not require premarket FDA approval, and copper tripeptide-1 is an established cosmetic ingredient in both the US and the EU. A cosmetic may make appearance claims; the moment it claims to heal wounds or regenerate collagen, it is making a drug claim.
We went through the same exercise with another peptide when its regulatory status shifted — our KPV peptide guide covers how a change at the FDA level reaches the patient in practice.
Where the “30-day cycle” comes from
Cycling advice for GHK-Cu — four weeks on, two to four weeks off — is presented online as though it were pharmacology. It is convention. There is no published human study establishing a cycle length, a washout period, or a rationale for either, for any route.
The one defensible argument for limiting continuous use of a copper-containing compound is not about tolerance or receptor downregulation. It is that copper delivered systemically bypasses the gut, which is the body’s main regulated checkpoint for copper absorption. That is a mechanistic reason for caution and for periodic monitoring, not a schedule derived from data.
Side effects and who should avoid GHK-Cu
Topical. The common adverse effect is irritation or contact dermatitis — redness, itching, tingling, most often when starting. True allergic contact dermatitis to copper is rare but documented. Reduced efficacy from layering with vitamin C or acids is a formulation problem rather than a safety one, but it is the most frequent reason people conclude a copper peptide “did nothing.”
Systemic. The documented regulatory concern is immunogenicity from aggregation and peptide-related impurities in compounded preparations, together with the absence of human safety data. Copper overload is biologically plausible — and serious — but we could find no case report of copper toxicity specifically from injected GHK-Cu. We are flagging it as theoretical rather than implying documented cases exist.
| Reason for caution | Why |
|---|---|
| Wilson’s disease or other copper metabolism disorders | Impaired biliary copper excretion means copper accumulates. Giving a copper-carrying compound is mechanistically contraindicated. |
| Pregnancy and breastfeeding | No data. That is the honest reason, and it is sufficient. |
| Known copper allergy | Straightforward avoidance. |
| Hepatic impairment | The liver handles copper. Reduced capacity is a reason to be careful. |
| Active malignancy | Unresolved in both directions. GHK-Cu is angiogenic early in repair, which argues for caution; laboratory work also reports growth inhibition in some tumour cell lines. There is no human data either way, and that uncertainty is itself the reason to hold off. |
One point of intellectual honesty on that last row: we could not find a specialty society, an FDA document, or a monograph publishing a contraindication list for GHK-Cu. Every list circulating online, including this one, is clinician-reasoned rather than guideline-backed. We would rather tell you that than present reasoning as established guidance.
How dosing is actually decided at RWA
Because there is no validated chart, the responsible process is a clinical one. In practice that means four things.
- Establish what you are actually trying to change. Skin quality, post-procedure recovery and general “anti-aging” are different goals with different reasonable answers — and for some of them a topical formulation, or a different modality such as microneedling with PRP, is the better-evidenced starting point.
- Review history and medications, with liver function and any copper metabolism history specifically in scope.
- Confirm current availability. Compounded peptide availability moves with FDA policy, and what a pharmacy could supply last year is not necessarily what it can supply now.
- Start conservatively and reassess rather than committing to a fixed cycle in advance.
If you want the broader picture of how peptides are prescribed and monitored here, our peptide therapy page lists what we currently offer, and our clinical team page covers who supervises it.
Frequently asked questions
What is the correct GHK-Cu injection dosage?
There is no established one. No published human trial of injected GHK-Cu exists at any dose, so any specific milligram figure you find online is convention or vendor guidance rather than evidence. Dosing decisions should be made by a clinician who has evaluated you.
Is GHK-Cu FDA approved?
No. GHK-Cu is not FDA-approved as a drug for any indication or route. Non-injectable GHK-Cu currently appears in Category 1 of the FDA’s 503A bulk drug substances list, which reflects interim enforcement discretion rather than approval. The injectable nomination has been withdrawn. Copper tripeptide-1 is separately permitted as a cosmetic ingredient, which is a different regulatory category entirely.
How long should a GHK-Cu cycle be?
No cycle length has been established in humans. The common “30 days on, then a break” advice is convention. The reasonable argument for not using a copper-containing compound continuously is that systemic copper bypasses the gut’s normal absorption control, which is a case for periodic review rather than a fixed calendar.
What percentage of GHK-Cu should a topical product contain?
The human topical studies do not state concentrations, so the commonly quoted 2 to 4% range is not study-derived. Consistency of use over 8 to 12 weeks is better supported by the available evidence than any particular percentage.
Can I use GHK-Cu with vitamin C?
Not in the same application. Copper catalyses the oxidation of ascorbic acid, and low pH destabilises the peptide-copper complex, so combining them degrades both. Use one in the morning and the other at night.
Is injectable GHK-Cu better than topical?
There is no evidence to support that comparison, because the injectable route has not been studied in people. The published human data, limited as it is, is topical.
Important medical disclaimer
These statements have not been evaluated by the Food and Drug Administration. GHK-Cu is not FDA-approved and is not intended to diagnose, treat, cure or prevent any disease. This article is educational, reflects the regulatory position at the time of writing, and is not medical advice or a substitute for evaluation by a qualified clinician. Peptide therapy is provided only after medical consultation, and availability of compounded preparations depends on current FDA compounding policy. Do not obtain or self-administer research-grade peptides purchased online.
Sources referenced
Pickart L, Margolina A. “Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data.” International Journal of Molecular Sciences, 2018;19(7):1987. · Badenhorst T, Svirskis D, Merrilees M, Bolke L, Wu Z. Journal of Aging Science, 2016;4:166. · Abdulghani A, Sherr A, Shirin S, Solodkina G, Tapia E, Wolf B, Gottlieb AB. Disease Management & Clinical Outcomes, 1998;1:136–141. · Leyden J, Stephens T, Finkey M, Appa Y, Barkovic S. Proceedings of the American Academy of Dermatology 60th Annual Meeting, 2002. · U.S. Food and Drug Administration, “Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act,” revised May 2026, and the accompanying Category 2 safety statements.
Medically reviewed by Biana Borchenko, FNP-BC (A4M) — Robertson Wellness & Aesthetics, Beverly Hills.
